Werewolf Therapeutics (NASDAQ:HOWL) Share Price Crosses Below Fifty Day Moving Average – Time to Sell?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) crossed below its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.99 and traded as low as $0.95. Werewolf Therapeutics shares last traded at $0.9857, with a volume of 560,895 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, Weiss Ratings raised Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. One investment analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Werewolf Therapeutics currently has an average rating of “Hold” and a consensus price target of $2.50.

Check Out Our Latest Analysis on HOWL

Werewolf Therapeutics Stock Down 4.3%

The company has a market capitalization of $47.91 million, a P/E ratio of -1.64 and a beta of 0.55. The business’s 50-day moving average price is $0.99 and its 200 day moving average price is $0.71.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings data on Friday, November 13th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. Analysts anticipate that Werewolf Therapeutics, Inc. will post -0.89 EPS for the current fiscal year.

Institutional Trading of Werewolf Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC raised its holdings in shares of Werewolf Therapeutics by 99.6% during the third quarter. Virtu Financial LLC now owns 90,749 shares of the company’s stock valued at $84,000 after purchasing an additional 45,282 shares during the last quarter. StoneX Group Inc. increased its stake in shares of Werewolf Therapeutics by 174.3% in the third quarter. StoneX Group Inc. now owns 54,856 shares of the company’s stock worth $51,000 after purchasing an additional 34,856 shares in the last quarter. Covestor Ltd purchased a new stake in shares of Werewolf Therapeutics in the third quarter worth $124,000. Vontobel Holding Ltd. bought a new stake in shares of Werewolf Therapeutics during the 3rd quarter valued at $55,000. Finally, Vilga Financial Planning LLC bought a new position in shares of Werewolf Therapeutics in the third quarter worth about $49,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.

Featured Articles

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.